For patients with symptomatic sickness requiring therapy, ibrutinib is frequently proposed depending on 4 phase III randomized clinical trials evaluating ibrutinib with chlorambucil monotherapy106 as well as other generally employed CIT combinations, particularly FCR, bendamustine additionally ritux